School of Pharmacy, Anhui Medical University, Hefei, 230032, China.
Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Int J Biol Sci. 2022 Jan 31;18(4):1612-1626. doi: 10.7150/ijbs.67852. eCollection 2022.
Alcohol-associated liver disease (ALD) encompasses a wide range of pathologies from simple steatosis to cirrhosis and hepatocellular carcinoma and is a global health problem. Currently, there are no effective pharmacological treatments for ALD. We have previously demonstrated that aging exacerbates the pathogenesis of ALD, but the underlying mechanisms are still poorly understood. Cellular repressor of E1A-stimulated genes 1 protein (CREG1) is a recently identified small glycoprotein that has been implicated in aging process by promoting cellular senescence and activating stress kinases. Thus, the current study aimed to explore the role of aging associated CREG1 in ALD pathogenesis and CREG1 as a potential therapeutic target. Hepatic and serum CREG1 protein levels were elevated in ALD patients. Elevation of hepatic CREG1 protein and mRNA was also observed in a mouse model of Gao-binge alcohol feeding. Genetic deletion of the gene in hepatocytes ( ) markedly exacerbated ethanol-induced liver injury, apoptosis, steatosis and inflammation. Compared to wild-type mice, mice had increased phosphorylation of hepatic stress kinases such as apoptosis signal-regulating kinase 1 (ASK1), c-Jun N-terminal kinase (JNK) and p38 but not TGF-β-activated kinase 1 (TAK1) or extracellular signal-regulated kinase (ERK) after alcohol feeding. , ethanol treatment elevated the phosphorylation of ASK1, JNK, and p38 in mouse hepatocyte AML-12 cells. This elevation was further enhanced by CREG1 knockdown but alleviated by CREG1 overexpression. Last, treatment with an ASK1 inhibitor abolished ethanol-induced liver injury and upregulated hepatic lipogenesis, proinflammatory genes and stress kinases in mice. Taken together, our data suggest that CREG1 protects against alcoholic liver injury and inflammation by inhibiting the ASK1-JNK/p38 stress kinase pathway and that CREG1 is a potential therapeutic target for ALD.
酒精相关性肝病(ALD)涵盖了从单纯脂肪变性到肝硬化和肝细胞癌等多种病理学变化,是一个全球性的健康问题。目前,尚无有效的治疗 ALD 的药物。我们之前的研究表明,衰老会加重 ALD 的发病机制,但其中的机制仍知之甚少。细胞 E1A 刺激基因 1 蛋白(CREG1)的抑制剂是一种新发现的小糖蛋白,它通过促进细胞衰老和激活应激激酶而参与衰老过程。因此,本研究旨在探讨与衰老相关的 CREG1 在 ALD 发病机制中的作用以及 CREG1 作为潜在治疗靶点的作用。ALD 患者的肝和血清 CREG1 蛋白水平升高。在酒精灌胃的小鼠模型中也观察到肝 CREG1 蛋白和 mRNA 的升高。肝细胞中基因的缺失()明显加重了乙醇诱导的肝损伤、细胞凋亡、脂肪变性和炎症。与野生型小鼠相比,在酒精喂养后, 小鼠肝脏中的应激激酶如凋亡信号调节激酶 1(ASK1)、c-Jun N 端激酶(JNK)和 p38 的磷酸化增加,但 TGF-β 激活激酶 1(TAK1)或细胞外信号调节激酶(ERK)没有增加。在 AML-12 细胞中,乙醇处理会增加 ASK1、JNK 和 p38 的磷酸化。CREG1 敲低会进一步增强这种增加,而 CREG1 过表达则会减轻这种增加。最后,ASK1 抑制剂的治疗消除了乙醇诱导的肝损伤,并上调了 小鼠肝脏的脂肪生成、促炎基因和应激激酶。总之,我们的数据表明,CREG1 通过抑制 ASK1-JNK/p38 应激激酶通路来保护肝脏免受酒精性肝损伤和炎症,CREG1 是治疗 ALD 的一个潜在靶点。